The Australian Evidence-Based Clinical Guideline For ADHD is a clinical practice guideline for the identification, diagnosis, and treatment of people with ADHD. Download the free PDF or order your printed copy by clicking the buttons below.
Launched in October 2022 by Federal Health Minister, Mark Butler, the Guideline integrates the best available evidence with multi-disciplinary clinical expertise and consumer preferences.
It provides a summary of scientific evidence and advice on the identification, diagnosis, support and treatment options for ADHD, including options with, and without, the use of medication for the estimated 1 million+ Australians with ADHD (The Social And Economic Costs Of ADHD In Australia, Deloitte Access Economics, 2019; Sciberras et al., 2022).
Comprising 111 recommendations for the diagnosis, assessment and treatment of ADHD across the lifespan, the guideline represents the most comprehensive guideline developed since the influential NICE 2018 guideline for “Attention Deficit Hyperactivity Disorder: Diagnosis and Management” produced for use in the UK.
The Australian guideline was developed by updating the evidence reviews, conducting new evidence reviews for questions not addressed by NICE and adapting the guidance to the Australian context.
Approved by the National Health and Medical Research Council (NHMRC), the guideline went through extensive reviews, including public consultation, where over 700 comments were addressed, an international expert review, and an expert methodological review commissioned by the NHMRC.